Misuraca Leonardo, Farah Bruno, Tchetche Didier
Unitè de Cardiologie Interventionelle, Clinique Pasteur, 45 Avenue de Lombez, 31076 Toulouse, France.
J Invasive Cardiol. 2013 Dec;25(12):680-2.
An 85-year-old woman was admitted to our institution for effort dyspnea. She had a history of mitral valve replacement with a 29 mm Carpentier-Edwards bioprosthesis (Edwards Lifesciences). Transthoracic echocardiography (TTE) showed aortic stenosis and senescence of the mitral bioprosthesis. The heart team opted for a transapical transcatheter aortic valve implantation (TAVI) and mitral valve-in-valve implantation (m-ViV). Two Edwards Sapien XT (ESXT) 29 mm devices were selected. To our knowledge, this is the first description of the concomitant transapical implantation of two 29 mm ESXTs for a combination of failed mitral bioprosthesis and native aortic stenosis.
一名85岁女性因劳力性呼吸困难入住我院。她有二尖瓣置换史,使用的是29毫米的Carpentier-Edwards生物瓣膜(爱德华生命科学公司)。经胸超声心动图(TTE)显示主动脉瓣狭窄和二尖瓣生物瓣膜老化。心脏团队选择经心尖经导管主动脉瓣植入术(TAVI)和二尖瓣瓣中瓣植入术(m-ViV)。选用了两枚29毫米的爱德华Sapien XT(ESXT)装置。据我们所知,这是首次描述为治疗二尖瓣生物瓣膜功能障碍合并原发性主动脉瓣狭窄而同时经心尖植入两枚29毫米ESXT。